Neuro-oncology: New therapeutic targets for diffuse intrinsic pontine glioma

Comment

. 2017 Apr;13(4):196.

doi: 10.1038/nrneurol.2017.39. Epub 2017 Mar 17.

Comment

Charlotte Ridler. Nat Rev Neurol. 2017 Apr.

. 2017 Apr;13(4):196.

doi: 10.1038/nrneurol.2017.39. Epub 2017 Mar 17.

No abstract available

Comment on

Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas.
Piunti A, Hashizume R, Morgan MA, Bartom ET, Horbinski CM, Marshall SA, Rendleman EJ, Ma Q, Takahashi YH, Woodfin AR, Misharin AV, Abshiru NA, Lulla RR, Saratsis AM, Kelleher NL, James CD, Shilatifard A. Piunti A, et al. Nat Med. 2017 Apr;23(4):493-500. doi: 10.1038/nm.4296. Epub 2017 Feb 27. Nat Med. 2017. PMID: 28263307 Free PMC article.
EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas.
Mohammad F, Weissmann S, Leblanc B, Pandey DP, Højfeldt JW, Comet I, Zheng C, Johansen JV, Rapin N, Porse BT, Tvardovskiy A, Jensen ON, Olaciregui NG, Lavarino C, Suñol M, de Torres C, Mora J, Carcaboso AM, Helin K. Mohammad F, et al. Nat Med. 2017 Apr;23(4):483-492. doi: 10.1038/nm.4293. Epub 2017 Feb 27. Nat Med. 2017. PMID: 28263309

Importance of immune monitoring approaches and the use of immune checkpoints for the treatment of diffuse intrinsic pontine glioma: From bench to clinic and vice versa (Review).
Scutti JAB. Scutti JAB. Int J Oncol. 2018 Apr;52(4):1041-1056. doi: 10.3892/ijo.2018.4283. Epub 2018 Feb 23. Int J Oncol. 2018. PMID: 29484440 Free PMC article. Review.
Genomic copy number gains of ErbB family members predict poor clinical outcomes in glioma patients.
Liu R, Qu Y, Chen L, Pu J, Ma S, Zhang X, Yang Q, Shi B, Hou P, Ji M. Liu R, et al. Oncotarget. 2017 Sep 23;8(54):92275-92288. doi: 10.18632/oncotarget.21228. eCollection 2017 Nov 3. Oncotarget. 2017. PMID: 29190914 Free PMC article.